Guideline Updates in Nontuberculous Mycobacterial Lung Disease Management

Read expert faculty member summaries of guideline updates in the diagnosis, monitoring, and treatment of patients with nontuberculous mycobacterial lung disease (NTM-LD).
person default
David E. Griffith, MD
Princy N. Kumar, MD, FIDSA, MACP
Format: Microsoft PowerPoint (.ppt)
File Size: 822 KB
Released: November 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Insmed Incorporated

Related Content

Dr David E. Griffith describes the complex role of in vitro susceptibility testing in the management of NTM lung disease, from Clinical Care Options (CCO)

person default David E. Griffith, MD Released: December 1, 2021

Dr Princy N. Kumar describes the safety monitoring required of first-line treatment for nontuberculous mycobacterial lung disease, from Clinical Care Options (CCO)

Princy N. Kumar, MD, FIDSA, MACP Released: November 30, 2021

Expert faculty discuss guideline recommendations for nontuberculous mycobacterial lung disease (NTM-LD), from Clinical Care Options (CCO)

Keira A. Cohen, MD
Program Director
person default David E. Griffith, MD Princy N. Kumar, MD, FIDSA, MACP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 19, 2021 Expired: November 18, 2022

From Clinical Care Options (CCO), a patient’s perspective on the road to diagnosis and life with nontuberculous mycobacterial (NTM) lung disease

person default Anonymous Patient Released: September 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings